Most people taking Qsymia notice reduced appetite within the first one to two weeks, but meaningful weight loss results are typically evaluated at 12 weeks. The medication uses a built-in dose escalation schedule, starting low for 14 days before stepping up to the recommended dose, so the full effects develop gradually over the first month.
What Happens in the First Two Weeks
Qsymia starts at a low introductory dose (3.75 mg phentermine / 23 mg topiramate) for the first 14 days. This isn’t the therapeutic dose. It’s designed to let your body adjust before stepping up. During this phase, you may notice some appetite suppression and possibly early side effects like tingling in your hands or feet, changes in how food tastes, trouble sleeping, or dry mouth. These are among the most commonly reported side effects at any stage of treatment.
After 14 days, the dose increases to 7.5 mg/46 mg, which is considered the standard recommended dose. This is when most people start feeling a more noticeable drop in hunger. The phentermine component works primarily as an appetite suppressant, while the topiramate component appears to influence energy balance through several pathways in the brain, though its exact weight loss mechanism isn’t fully understood.
The 12-Week Checkpoint
Twelve weeks on the standard dose is the first formal benchmark. At that point, you should have lost at least 3% of your starting body weight. If you weighed 220 pounds when you began, that means roughly 6.5 pounds or more. If you haven’t hit that threshold, your prescriber will either discuss stopping the medication or increasing the dose.
The higher dose follows the same pattern: a 14-day step-up period at 11.25 mg/69 mg, then a full increase to the maximum dose of 15 mg/92 mg. You’ll stay on that maximum dose for another 12 weeks before the next evaluation. At that point, the target is 5% loss from your original baseline weight. If you haven’t reached it, the prescribing guidelines recommend discontinuing Qsymia rather than continuing indefinitely without results.
What Clinical Trials Show at One Year
The CONQUER trial, published in The Lancet, tracked patients over 56 weeks and provides the clearest picture of what sustained use looks like. Patients on the standard dose (7.5 mg/46 mg) lost an average of 8.1 kg, about 18 pounds, representing a 7.8% reduction in body weight. Those on the higher dose (15 mg/92 mg) lost an average of 10.2 kg, roughly 22.5 pounds, or 9.8% of their body weight. The placebo group lost just 1.4 kg over the same period.
These are averages, so individual results vary. But the gap between the medication groups and placebo is substantial, and it widens over time. Most of the weight loss accumulates in the first six to nine months, with results plateauing after that. Qsymia is approved for long-term use alongside a reduced-calorie diet and increased physical activity.
Why the Gradual Ramp-Up Matters
The slow titration schedule can feel frustrating if you’re eager for results, but it serves a purpose. Both active ingredients affect brain chemistry, and starting at full strength increases the likelihood and severity of side effects. The two-week introductory phase gives your nervous system time to adjust. Common early side effects like tingling, dizziness, constipation, and insomnia tend to be most noticeable during dose changes and often ease as your body adapts.
Your kidneys also respond to the medication early on. Creatinine levels (a marker of kidney function) tend to rise during the first 4 to 8 weeks, then gradually come back down, though they may stay slightly above your pre-treatment baseline. This is expected and typically monitored through routine bloodwork.
A Realistic Timeline to Expect
Here’s a practical breakdown of what the first several months generally look like:
- Days 1 to 14: Low introductory dose. Mild appetite changes possible. Side effects may appear.
- Weeks 3 to 4: Standard dose begins. Appetite suppression becomes more noticeable for most people.
- Weeks 4 to 8: Weight loss starts to become visible on the scale. Side effects often begin to settle.
- Week 12: First evaluation point. You should have lost at least 3% of your starting weight. If not, your dose may be increased or the medication stopped.
- Weeks 12 to 24 (if dose increases): Second evaluation period at the higher dose, targeting 5% total weight loss.
- Months 6 to 12: Weight loss continues to accumulate but gradually slows, with most results achieved by month nine.
If you’re a few weeks in and the scale hasn’t moved much, that’s not unusual. The medication’s effectiveness is measured in months, not days. The 12-week checkpoints exist precisely because individual response times vary, and a structured evaluation prevents people from staying on a medication that isn’t working for them.